CSIMarket
 


Precision Biosciences Inc  (DTIL)
Other Ticker:  
 

Precision Biosciences Inc's Tangible Leverage Ratio

DTIL's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


In Spite of the repayements of liabilities of -8.38%, in III Quarter 2023 ,Tangible Leverage Ratio deteriorated to 4.82 is above the company's typical Tangible Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2023, 128 other companies have achieved lower Tangible Leverage Ratio than Precision Biosciences Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 2373 to 3091 .

Explain Tangible Leverage Ratio?
What is DTIL Market Share?
What are DTIL´s Total Liabilities?


DTIL Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change -65.92 % -67.84 % -42.85 % -33.7 % -17.07 %
Y / Y Total Liabilities Change -27.79 % -23.94 % 47.12 % 47.71 % 48.98 %
Tangible Leverage Ratio MRQ 4.82 4.54 4.25 3.01 2.27
DTIL's Total Ranking # 3091 # 2373 # 1794 # 2415 # 2461
Seq. Tangible Equity Change -13.55 % -15.94 % -34.58 % -28.3 % -18.43 %
Seq. Total Liabilities Change -8.38 % -10.14 % -7.55 % -5.13 % -3.5 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 129
Healthcare Sector # 785
Overall Market # 3091


Tangible Leverage Ratio Statistics
High Average Low
14.4 2.71 0.56
(Mar 31 2019)   (Jun 30 2019)




Financial Statements
Precision Biosciences Inc's Tangible Equity $ 28 Millions Visit DTIL's Balance sheet
Precision Biosciences Inc's Total Liabilities $ 135 Millions Visit DTIL's Balance sheet
Source of DTIL's Sales Visit DTIL's Sales by Geography


Cumulative Precision Biosciences Inc's Tangible Leverage Ratio

DTIL's Tangible Leverage Ratio for the trailling 12 Months

DTIL Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth -65.92 % -67.84 % -42.85 % -33.7 % -17.07 %
Y / Y Total Liabilities TTM Growth -27.79 % -23.94 % 47.12 % 47.71 % 48.98 %
Tangible Leverage Ratio TTM 3.95 3.18 2.57 2.16 1.8
Total Ranking TTM # 1627 # 1409 # 1226 # 1182 # 852
Seq. Tangible Equity TTM Growth -13.55 % -15.94 % -34.58 % -28.3 % -18.43 %
Seq. Total Liabilities TTM Growth -8.38 % -10.14 % -7.55 % -5.13 % -3.5 %


On the trailing twelve months basis Despite of the repayements of liabilities of -8.38% in the trailing twelve months ending in III Quarter 2023, Tangible Leverage Ratio improved to 3.95, above Precision Biosciences Inc's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 2, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Precision Biosciences Inc. While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 80 to 3197.

Explain Tangible Leverage Ratio?
What is DTIL Market Share?
What are DTIL´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 3
Healthcare Sector # 27
Within the Market # 3091


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.54 0.17 0.01
(Sep 30 2023)   (Jun 30 2021)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Cidara Therapeutics Inc   6.90 $ 55.430  Millions$ 8.038  Millions
Precision Biosciences Inc  4.82 $ 135.281  Millions$ 28.086  Millions
Lineage Cell Therapeutics Inc   4.05 $ 38.036  Millions$ 9.394  Millions
Alector Inc   3.14 $ 509.840  Millions$ 162.555  Millions
Biomx Inc   3.09 $ 25.181  Millions$ 8.154  Millions
Humacyte Inc   3.04 $ 112.392  Millions$ 36.993  Millions
Curis Inc   2.87 $ 59.122  Millions$ 20.609  Millions
Sutro Biopharma Inc   2.84 $ 319.387  Millions$ 112.347  Millions
Pluri Inc   2.74 $ 30.211  Millions$ 11.038  Millions
Valneva Se  2.59 $ 371.633  Millions$ 143.637  Millions
Adaptimmune Therapeutics Plc  2.38 $ 208.509  Millions$ 87.745  Millions
Ladrx Corporation  2.18 $ 2.100  Millions$ 0.965  Millions
Qiagen N v   2.10 $ 1,692.857  Millions$ 805.211  Millions
X4 Pharmaceuticals Inc  2.08 $ 104.583  Millions$ 50.243  Millions
Meiragtx Holdings Plc  1.93 $ 175.308  Millions$ 90.746  Millions
Omega Therapeutics Inc   1.86 $ 141.765  Millions$ 76.043  Millions
Inhibrx Inc   1.85 $ 239.481  Millions$ 129.595  Millions
Estrella Immunopharma Inc   1.72 $ 17.281  Millions$ 10.069  Millions
Aptose Biosciences Inc   1.68 $ 13.100  Millions$ 7.776  Millions
Sana Biotechnology Inc   1.60 $ 265.588  Millions$ 166.030  Millions
Orchard Therapeutics Plc  1.59 $ 122.008  Millions$ 76.937  Millions
Adaptive Biotechnologies Corporation  1.50 $ 355.950  Millions$ 237.108  Millions
Cel sci Corporation  1.33 $ 17.313  Millions$ 13.017  Millions
Poseida Therapeutics Inc   1.33 $ 156.729  Millions$ 118.112  Millions
Arcellx Inc   1.31 $ 348.090  Millions$ 266.128  Millions
Pharmacyte Biotech Inc   1.27 $ 42.110  Millions$ 33.218  Millions
Bio techne Corp  1.26 $ 567.754  Millions$ 449.399  Millions
Adma Biologics Inc   1.25 $ 184.901  Millions$ 147.431  Millions
Autolus Therapeutics Plc  1.22 $ 220.089  Millions$ 180.518  Millions
Protalix Biotherapeutics inc   1.17 $ 44.820  Millions$ 38.247  Millions

Date modified: 2024-02-27T10:03:32+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com